Results 101 to 110 of about 3,560 (171)

No increased risk of hepatic enzyme abnormalities with non-peptidic thrombopoietin receptor agonists in immune thrombocytopenia: A meta-analysis of randomized controlled trials. [PDF]

Exp Ther Med
Shen N, Wu R, Lu T, Liu S, Jiang Y, Yan J, Ning T, Dong C, Li J, Zhu S.   +9 more
europepmc   +1 more source

The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity. [PDF]

Pharmaceuticals (Basel), 2023
Hamed EM, Ibrahim ARN, Meabed MH, Khalaf AM, El Demerdash DM, Elgendy MO, Saeed H, Salem HF, Rabea H.   +8 more
europepmc   +1 more source

Effectiveness of Rituximab, Belimumab, and Thrombopoietin Receptor Agonists in Refractory Immune Thrombocytopenia Associated With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Ohta R, Ryu Y, Ichinose K.
europepmc   +1 more source

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus. [PDF]

Ann Hematol, 2023
Pulanić D, Bátorová A, Bodó I, Červinek L, Ionita I, Lissitchkov T, Melikyan A, Podolak-Dawidziak M.   +7 more
europepmc   +1 more source

Safety of non‑peptide thrombopoietin receptor agonists in patients with immune thrombocytopenia: A systematic review and meta‑analysis of short‑term double‑blind randomized clinical trials. [PDF]

Exp Ther Med, 2023
Shen N, Qiao J, Jiang Y, Yin H, Li M, Zhu S, Li J.   +6 more
europepmc   +1 more source

Unintended First-Trimester Exposure to Two Distinct Thrombopoietin Receptor Agonists in Consecutive Pregnancies Without Maternal or Fetal Harm [PDF]

Turk J Haematol
Köseoğlu FD, Kum A.
europepmc   +1 more source

Successful Reswitching of Thrombopoietin Receptor Agonists: Two Cases of Immune Thrombocytopenia and Severe Aplastic Anemia. [PDF]

Intern Med
Itoh K, Otsuki N, Suzuki Y, Kiriba C, Kuwata A, Tsutani H, Iwasaki H, Mitsuke Y.   +7 more
europepmc   +1 more source

Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy. [PDF]

Mediterr J Hematol Infect Dis, 2023
Napolitano M, Vianelli N, Ghiotto L, Cantoni S, Carli G, Carpenedo M, Carrai V, Consoli U, Giuffrida G, Lucchini E, Rossi E, Santoro C, Rodeghiero F.   +12 more
europepmc   +1 more source

Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients. [PDF]

Am J Hematol
Marques C, Moulis G, Roussotte M, Bonnotte B, Viallard JF, Graveleau J, Lobbes H, Costedoat-Chalumeau N, Deroux A, Gobert D, Dossier A, Gilardin L, Lambotte O, Dufrenoy M, Mahévas M, Michel M, Sève P, Godeau B.   +17 more
europepmc   +1 more source

Can COVID-19 Increase Platelet in Adult Immune Thrombocytopenia During the TPO-RA Administration? A Real-World Observational Study

Journal of Blood Medicine
Xiaoyu Wang,* Yingqiao Zhu,* Dan Liu, Lijun Zhu, Juan Tong, Changcheng Zheng Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People’s ...
Wang X, Zhu Y, Liu D, Zhu L, Tong J, Zheng C   +5 more
doaj